**Basic Study**

Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Teneligliptin mitigates diabetic cardiomyopathy

Gulao Zhang, Yuan Liu, Yanfeng Liu, Xiantao Huang, Yu Tao, Zhenhuan Chen, Hengli Lai

**Abstract**

**BACKGROUND**

Diabetic cardiomyopathy (DCM), which is a complication of diabetes, poses a great threat to public health. Recent studies have confirmed the role of NOD-like receptor protein 3 (NLRP3) activation in DCM development through the inflammatory response. Teneligliptin is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor used to treat diabetes. Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells.

**AIM**

This study examined the therapeutic effects of teneligliptin on DCM in diabetic mice.

**METHODS**

Streptozotocin (STZ) was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin.
RESULTS
Marked increases in cardiomyocyte area and heart weight/tibia length; reductions in fractional shortening, ejection fraction, and heart rate; increases in creatine kinase-MB (CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels; and upregulated NADPH oxidase 4 (NOX-4) were observed in diabetic mice, all of which were significantly reversed by teneligliptin. Moreover, NLRP3 inflammasome activation and increased release of interleukin-1β (IL-1β) in diabetic mice were inhibited by teneligliptin. Primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5, 5 μM) for 24 h. NLRP3 inflammasome activation and the increases in CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes were markedly inhibited by teneligliptin, and p-adenosine 5′-monophosphate (AMP)-activated protein kinase (p-AMPK) levels were increased. Furthermore, the beneficial effects of teneligliptin on high glucose-induced cardiomyocytes were abolished by the AMPK signaling inhibitor compound C.

CONCLUSION
Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome.

Key Words: Diabetic cardiomyopathy; Teneligliptin; NLRP3; AMPK; IL-1β


Core Tip: Teneligliptin mitigated diabetic cardiomyopathy by mitigating the activation of NOD-like receptor protein 3 (NLRP3) inflammasome. Teneligliptin reversed markedly increased cardiomyocyte area and heart weight/tibia length, reduced fractional shortening, ejection fraction, and heart rate, increased creatine kinase-MB
(CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels, and upregulated NADPH oxidase 4 in Streptozotocin induced diabetic mice. Teneligliptin repressed activated NLRP3 inflammasome and increased CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes, accompanied by an upregulation of p-adenosine 5'-monophosphate (AMP)-activated protein kinase (p-AMPK).

**INTRODUCTION**

With the rapid development of international society and the economy, living standards have improved qualitatively. However, the prevalence of diseases has increased greatly, and diabetes mellitus (DM) is common. According to the International Diabetes Federation, in 2019, 1 in 11 adults aged ≥20-79 years were affected by diabetes, the morbidity rate of which reached 9.3% in the global adult population and is expected to reach 700 million by 2045[1], posing a threat to public health. As a complication of DM, diabetic cardiomyopathy (DCM) is a condition in which the heart has abnormal myocardial structure and function in the absence of coronary artery disease, severe valvular lesions, or other conventional cardiovascular factors. DCM is characterized by lipid accumulation in the heart, myocardial fibrosis, and an increased probability of myocardial cell death, leading to left ventricular remodeling, hypertrophy, and diastolic dysfunction, which, in turn, contributes to systolic dysfunction[2]. The pathophysiological mechanism of DCM is related to an abnormal glucose supply and lipid metabolism due to increased oxidative stress (OS), cellular activation regulated by multiple inflammatory pathways, extracellular damage, pathological cardiac remodeling, and diastolic and systolic dysfunction induced by DM[3]. NOD-like receptor protein 3 (NLRP3) is an inflammasome that can be found in both immune and nonimmune cells, such as macrophages, cardiomyocytes, and fibroblasts. NLRP3 is upregulated in multiple diseases, including DCM and atherosclerosis[4]. Activation of the NLRP3 inflammasome has been shown to participate in DCM and the death of cardiomyocytes. In response to a variety of pathological factors, the NLRP3 inflammasome and the expression of downstream cytokines are triggered, leading to a
cascade of inflammatory reactions and causing damage to myocardial cells\[6\]. Furthermore, NLRP3 activation correlates with reactive oxygen species (ROS) production. Under high-glucose conditions, ROS levels are elevated, which is important for NLRP3 inflammasome activation. In addition, ROS activate the NLRP3 inflammasome mainly by forcing cytochrome C to enter the cytoplasm and bind to NLRP3. NLRP3 is inactivated by inhibiting ROS production, which alleviates high glucose-induced myocardial cell damage\[6\]. Therefore, NLRP3 is a critical target for treating DCM.

Teneligliptin (Figure 1A) is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor developed by Mitsubishi Pharmaceutical Company in Japan that is mainly used to treat type II diabetes. By suppressing the inactivation of glucagon-like peptide in vivo by selectively inhibiting the activity of DPP-IV, teneligliptin promotes the production of insulin by islet cells and reduces the concentration of glucagon, thereby reducing blood glucose. Teneligliptin is well tolerated and has a low incidence of adverse reactions\[7,8\]. Recently, teneligliptin was shown to have a promising suppressive effect on inflammation\[9\] and OS\[10\]. Teneligliptin has been used to treat T2DM patients with renal impairment, including those with end-stage renal disease (ESRD). Moreover, teneligliptin has cytoprotective effects on myocardial cells\[11\]. Our research will examine the possible therapeutic effect of teneligliptin on DCM in diabetic mice.

MATERIALS AND METHODS

Animal experiments

The streptozotocin (STZ) solution (#S0130, Sigma–Aldrich, USA) was prepared with citric acid/sodium citrate buffer, and 55 mg/kg STZ was administered to C57BL/6 male mice by intraperitoneal injection for 5 consecutive days. One week later, blood was collected from the tail vein, and fasting blood glucose levels were detected by a Roche blood glucose meter. The mouse model of DCM was considered successfully constructed if the fasting blood glucose level was higher than 16.7 mmol/L. The mice were divided into three groups: vehicle, STZ, and teneligliptin (#SML3077;
Sigma–Aldrich, USA). In the vehicle and STZ groups, normal mice and diabetic mice received oral doses of normal saline. In the teneligliptin group, diabetic mice were orally administered 30 mg/kg teneligliptin for 4 wk. This study was approved by the Ethics Committee of Jiangxi Provincial People's Hospital.

**Measurement of heart function**

The mice were anesthetized by an intraperitoneal injection of sodium pentobarbital to maintain a heart rate of approximately 300 beats/min and then placed on a thermostatic heating plate connected to a high-resolution small animal ultrasonic apparatus (VisualSonics, Canada). The following parameters were recorded: end-systolic diameter (ESD) and volume (ESV), end-diastolic diameter (EDD) and volume (EDV), and heart rate. Fractional shortening was calculated as (EDD-ESD)/EDD×100%, while the ejection fraction was calculated as (EDV-ESV)/EDV×100%.

**Detection of myocardial injury indicators and interleukin-1β (IL-1β)**

The levels of creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH), and IL-1β were detected by ELISA (R&D Systems, USA). The supernatant was collected and added to a 96-well plate, and the standards were added. After incubation for 1.5 h, the conjugate solution was added to the wells, after which the plates were incubated for another 1.5 h. Next, tetramethylbenzidine (TMB) solution (#861510, Sigma–Aldrich, USA) was added, followed by a 15 min of incubation. Finally, the stop solution was added to stop the reaction, after which the optical density was detected with a microplate reader (MD, USA) at 450 nm.

**Hematoxylin-eosin (H&E) staining**

The collected myocardium was rinsed with water for 2 h. After being dehydrated with different concentrations of ethanol, the tissues were dehydrated with xylene until transparent, embedded for 1 h and then sliced. After being heated, dewaxed, and hydrated, the sections were immersed in water and subsequently stained with hematoxylin aqueous reagent for 2-3 min. After being differentiated in hydrochloric acid ethanol, the sections were stained with the blue-returning reagent for several
seconds. After being stained with eosin for 180 s, images were obtained using an inverted microscope (Nikon, Japan).

**Real-time PCR**

*Total RNA was extracted* from tissues or cells with TRIzol reagent, after which the *RNA concentration was quantified* with an ultraviolet spectrophotometer (Hach, USA). *RNA was transcribed to cDNA* using a cDNA synthesis kit (SolelyBio, China). Subsequently, *PCR was performed by using* an SYBR Premix Ex TaqII kit (Takara, Japan), and *gene expression* was determined by using the 2^-ΔΔCt method.

**Western blot analysis**

Tissues or cells were lysed to extract total proteins, followed by quantification using the BCA method. The proteins were separated by 12% SDS-PAGE and subsequently transferred to PVDF membranes. After the membranes were blocked, primary antibodies against NADPH oxidase 4 (NOX-4) (1:2000, #14347-1-AP, Proteintech, USA), NLRP3 (1:2000, #14347-1-AP, Proteintech, USA), Caspase-1 (1:2000, 22915-1-AP, Proteintech, USA), p-AMPK (1:1000, #4186, Cell Signaling Technology, USA), and β-actin (#4970, Cell Signaling Technology, USA) were used. Then, secondary antibodies (1:2000, #7074, #7076; Cell Signaling Technology, USA) were added. The bands were visualized with enhanced chemiluminescence (ECL) solution for quantification.

**Primary cardiomyocyte culture**

Immature mice (0-2 days old) were disinfected by immersion in 75% alcohol for 1-2 min. Then, a small incision was made under the sternum with sterilized ophthalmic scissors, after which the heart was collected and was placed in a Petri dish with precooled Hanks solution. The heart was then cut into 1 mm³ pieces with scissors on an ultraclean table, followed by the addition of 7 mL of 0.1% type II collagenase. The rubber plug was blocked, the sealing membrane was added, and cells were then placed in a 37°C incubator for 10 min until the cells naturally precipitated. The supernatant was discarded, and the digestion was terminated by gently mixing the solution approximately 60 times with a pipettor for 15 min. Then, the cell suspension was transferred to high-glucose DMEM. The cell suspension obtained from each digestion
was mixed until the tissue block was completely digested. The supernatant was discarded after being centrifuged at 1000× rpm for 10 min, and an appropriate amount of complete medium was subsequently mixed with a 100 μm nylon screen and inoculated into the culture flask, which was subsequently cultured at 37°C in a 5% carbon dioxide incubator. After 90 min, the supernatant was mostly purified, and the cardiomyocytes were transferred to another culture flask for further culture.

**Statistical analysis**

The data are presented as the mean ± standard deviation and were analyzed using one-way analysis of variance with GraphPad Prism software 6.0. P < 0.05 was considered to indicate a statistically significant difference.

**RESULTS**

**Teneligliptin ameliorated myocardial hypertrophy in STZ-induced diabetic mice**

WGA staining was used to detect myocardial hypertrophy. Cardiomyocyte area in STZ-treated mice increased from 203.6 μm² to 287.5 μm² and was markedly reduced to 216.7 μm² by teneligliptin (Fig. 1B). Moreover, the heart weight/tibia length in STZ-treated mice increased from 6.4 mg/mm to 8.3 mg/mm and was decreased to 6.2 mg/mm by teneligliptin (Fig. 1C). Moreover, teneligliptin alleviated myocardial hypertrophy.

**Teneligliptin improved heart function in STZ-induced diabetic mice**

H&E staining (Fig. 2A) showed that myocardial cells in the vehicle group exhibited a normal morphology, complete structure, dense and regular arrangement, and uniform distribution of nuclei. However, myocardial cells in diabetic mice were hypertrophic with a fuzzy structure, disordered arrangement, and some fiber breakage. The morphological structures of myocardial cells in the teneligliptin group were neat with relatively regular arrangements and improvements in hypertrophy and fiber breakage. The fractional shortening of diabetic mice decreased from 53.5% to 38.7% and was markedly increased to 49.6% by teneligliptin (Fig. 2B). Furthermore, the ejection fractions in the vehicle, STZ, and teneligliptin groups were 87.6%, 73.5%, and 85.5%, respectively (Fig. 2C). The heart rates of the diabetic mice decreased from 462.5
beats/minute to 458.7 beats/minute and then increased to 468.3 beats/minute in response to teneligliptin (Fig. 2D). The heart function of diabetic mice was improved by teneligliptin.

**Teneligliptin reduced the expression of myocardial injury indicators in STZ-induced diabetic mice**

CK-MB levels in diabetic mice increased from 303.5 U/L to 888.8 U/L but were markedly reduced to 578.8 U/L by teneligliptin (Fig. 3A). Moreover, AST levels in the vehicle, STZ, and teneligliptin groups were 176.3, 522.6, and 371.8 U/L, respectively (Fig. 3B). LDH levels in diabetic mice increased from 262.7 U/L to 697.5 U/L and then decreased to 451.2 U/L in response to teneligliptin (Fig. 3C).

**Teneligliptin reduced NOX4 levels in diabetic mice**

NOX4 is a critical pathological factor in DCM. The increase in NOX4 levels in diabetic mice was markedly inhibited by teneligliptin (Fig. 4A-B).

**Teneligliptin reduced activation of the NLRP3 inflammasome in the heart in diabetic mice**

First, NLRP3 and caspase-1 were notably upregulated in diabetic mice but markedly decreased by teneligliptin (Fig. 5A). Moreover, IL-1β levels in diabetic mice increased from 2.5 to 3.4 μmol/mg protein and then decreased to 2.8 μmol/mg protein in response to teneligliptin (Fig. 5B). The suppressive effect of teneligliptin on the NLRP3 inflammasome in the heart was observed.

**Teneligliptin prevented activation of the NLRP3 inflammasome in the heart and injury in cardiomyocytes**

Primary mouse cardiomyocytes were extracted and treated with high glucose (30 mmol/L) with or without teneligliptin (2.5, 5 μM) for 24 h. NLRP3 and caspase-1 Levels in cardiomyocytes were markedly increased by 30 mmol/L glucose but were inhibited by 2.5 and 5 μM teneligliptin (Fig. 6A). Moreover, IL-1β levels in the control, high glucose, 2.5 μM teneligliptin, and 5 μM teneligliptin groups were 1.5, 2.7, 2.1, and 1.8 μmol/mg protein, respectively (Fig. 6B). CK-MB levels increased from 98.8 U/L to 288.5 U/L in 30 mmol/L glucose-treated cardiomyocytes and then decreased to 205.6 and
155.7 U/L in response to 2.5 and 5 μM teneligliptin, respectively. Furthermore, AST levels in the control, high glucose, 2.5 μM teneligliptin, and 5 μM teneligliptin groups were 105.6, 223.9, 170.5, and 146.6 U/L, respectively (Fig. 6C). The suppressive effect of teneligliptin on the NLRP3 inflammasome in cardiomyocytes was observed.

**Treatment with teneligliptin increased the phosphorylation of AMPK in cardiomyocytes under high glucose conditions**

AMPK signaling reportedly regulates the NLRP3 inflammasome[13]. The decrease in p-AMPK in cardiomyocytes was reversed by 30 mmol/L glucose, and this effect was markedly reversed by 2.5 and 5 μM teneligliptin (Fig. 7), suggesting that teneligliptin might affect AMPK signaling.

**Inhibiting AMPK abolished the beneficial effects of teneligliptin on high glucose-induced cardiomyocytes**

For verification, primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 μM) or compound C (10 μM) for 24 h. First, the reduction in p-AMPK in 30 mmol/L glucose-treated cardiomyocytes was notably attenuated by teneligliptin, and this effect was reversed by compound C (Fig. 8A). Furthermore, the increase in NLRP3 observed in 30 mmol/L glucose-treated cardiomyocytes was strongly reduced by teneligliptin but was elevated by compound C (Fig. 8B). Moreover, CK-MB levels increased from 102.5 U/L to 297.6 U/L in 30 mmol/L glucose-treated cardiomyocytes and then greatly decreased to 162.3 U/L in response to teneligliptin. After the administration of compound C, CK-MB levels were reversed to 255.2 U/L. AST levels in the control, high glucose, teneligliptin, and teneligliptin+ compound C groups were 112.3, 235.6, 155.3, and 215.3 U/L, respectively (Fig. 8C). The beneficial effects of teneligliptin on high glucose-induced cardiomyocytes were abolished by AMPK inhibition.

**DISCUSSION**

Studies have shown that NLRP3 is activated during DCM development through the inflammatory response and that teneligliptin exerts anti-inflammatory and protective
effects on myocardial cells. In this study, we established an STZ-induced diabetic model and found that teneligliptin significantly inhibited cardiac hypertrophy and reduced fractional shortening and the ejection fraction induced by diabetes. Additionally, teneligliptin significantly reversed diabetes-induced increases in CK-MB, AST and LDH. In addition, activation of the NLRP3 inflammasome and the increased release of IL-1β in diabetic mice were inhibited by teneligliptin, which was accompanied by the upregulation of p-AMPK. The same results were obtained in primary mouse cardiomyocytes treated with high glucose.

Teneligliptin is a low-cost oral hypoglycemic dipeptidyl peptidase-4 inhibitor that is used for diabetes treatment. Harmanjit Singh et al searched 13 eligible studies containing data on 15,720 subjects and showed similar efficacy (or better) and safety of teneligliptin compared to other DPP4Is. The average cost per tablet of teneligliptin (20 mg) was markedly lower than that of sitagliptin, vildagliptin, or other commonly used DPP4Is. Teneligliptin has various effects on both cardiovascular disease and other disorders. Teneligliptin can improve vascular endothelial function by improving flow-mediated vascular dilatation through divergent actions, including changes in circulating endothelial progenitor cells. Teneligliptin-induced vasodilation occurs via the activation of protein kinase G, SERCA pumps and protein kinase G channels. A systematic review of thirteen randomized controlled trials that enrolled 2853 patients showed that teneligliptin was an effective and safe therapeutic option for patients with T2DM as a monotherapy and add-on therapy.

Evogliptin, which is another DPP4 inhibitor, lowered the blood glucose and HbA1c levels and improved insulin sensitivity, cardiac systolic/diastolic function, hypertrophy, and fibrosis by reducing the accumulation of lipid droplets in the myocardium by suppressing CD36, Acyl CoA synthetase long chain family member 1, fatty acid binding protein 3, peroxisome proliferator activated receptor gamma, and diacylglycerol O-acyltransferase 1 and increasing the phosphorylation of forkhead box protein O1, indicating its inhibition. This effect was consistent with the findings of the present study. The evogliptin-mediated improvement in mitochondrial function and
reduction in damage were achieved through the activation of peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC1α)/nuclear respiratory factor 1/ transcription factor A, mitochondrial, which activates mitochondrial biogenesis[18], indicating that teneligliptin may affect mitochondrial function, and future studies should examine this aspect. Zhang et al. used alloxan-induced diabetic rabbits and showed that alogliptin prevented cardiac diastolic dysfunction by inhibiting ventricular remodeling by improving mitochondrial function and increasing mitochondrial biogenesis[19]. Furthermore, the effect of alogliptin on heart function was similar to our findings.

Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells, and DPP4 inhibitors have been reported to be associated with mitochondrial metabolism. Notably, teneligliptin enhances SIRT1 protein expression and activity through USP22, a ubiquitin-specific peptidase. Activated SIRT1 prevents high glucose-induced PRDX3 acetylation by SIRT3, resulting in the inhibition of PRDX3 hyperoxidation and thereby enhancing mitochondrial antioxidant defense[20].

In rat cardiac microvascular endothelial cells, teneligliptin significantly ameliorated the reduction in mitochondrial membrane potential induced by hypoxia/reoxygenation, indicating that teneligliptin could affect mitochondrial function[21]. In 5/6-nephrectomized (CKD) mice, indoxyl sulfate induced mitochondrial dysfunction by decreasing the expression of PGC-1α and inducing autophagy, as well as decreasing the mitochondrial membrane potential, and teneligliptin reversed this effect[22]. In summary, although teneligliptin has been reported to have anti-inflammatory and protective effects on myocardial cells, future studies should focus on its ability to improve mitochondrial metabolism.

NLRP3 is a NOD-like receptor sensor molecule[23] that belongs to the cytoplasmic NOD family of pattern recognition receptors. After being activated, NLRP3 undergoes self-oligomerization and assembles with ASC and the protease Caspase-1 to form the NLRP3 inflammasome. This process results in the production of the active form of the Caspase-1 p10/p20 splicer and induces the conversion of the proinflammatory cytokines IL-1β and IL-18 from their immature forms to their active forms, inducing an
inflammatory response\textsuperscript{[24]}, the NLRP3 inflammasome triggers a form of cell death known as pyroptosis. NLRP3 activation triggers the autocatalytic activation of Caspase-1, which drives the cleavage of the Gasdermin D protein to produce N\textsuperscript{c}-segment protein fragments that bind to phospholipid proteins on the cell membrane, form holes, and release inflammatory factors. Subsequently, cells continue to expand until the membrane ruptures, which is the process of pyroptosis\textsuperscript{[25]}. NLRP3 inhibition improves insulin sensitivity in obese mice, suggesting that NLRP3 may participate in metabolism-related diseases such as diabetes\textsuperscript{[26]}. In addition, hyperglycemia reportedly activates NLRP3 inflammasome-mediated pyroptosis in myocardial cells, and knocking down NLRP3 in DCM rats reduces the inflammatory response in myocardial tissues, inhibits the occurrence of myocardial pyroptosis and myocardial interstitial fibrosis, and improves cardiac function\textsuperscript{[27, 28]}. These findings suggest that the NLRP3 inflammasome is involved in DCM development. In our study, DCM model mice were generated by STZ injection, and the results were verified by assessing myocardial hypertrophy, impaired heart function, and myocardial injury indicator production; these findings were consistent with previous studies\textsuperscript{[29, 30]}. Following the administration of teneligliptin, myocardial hypertrophy was alleviated, heart function was improved, and myocardial injury indices were reduced, suggesting that teneligliptin could alleviate DCM in mice. Moreover, the NLRP3 inflammasome was activated in both DCM mice and primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, which was consistent with the findings of Song\textsuperscript{[31]} and Shi\textsuperscript{[32]}. Following the administration of teneligliptin, NLRP3 inflammasome activity was inhibited in both DCM mice and primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, suggesting that the effect of teneligliptin might be mediated by inhibition of the NLRP3 inflammasome. AMPK regulates NLRP3 inflammasome activation through multiple pathways, such as mitochondrial homeostasis, endoplasmic reticulum stress, autophagy, and SIRT1 activation. p-AMPK/AMPK is an important sensor molecule that regulates bioenergy homeostasis and reduces the activation of NF-κB to control the inflammatory response mediated by the NLRP3 inflammasome\textsuperscript{[33]}. A previous study showed that autophagy
was induced, mitochondrial ROS production was reduced, and IL-1β secretion was inhibited by mTOR inhibitors\(^\text{[34]}\). Autophagy is facilitated by AMPK through the activation of ULK or inhibition of the mTOR pathway. Furthermore, NLRP3 inflammasome activity is negatively regulated by autophagy through different mechanisms\(^\text{[35]}\). In our study, AMPK signaling was inhibited in primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, which is consistent with the findings of Yang\(^\text{[33]}\). The suppressive effect of 30 mmol/L glucose on AMPK signaling was reversed by teneligliptin, suggesting that the AMPK pathway mediates the effects of teneligliptin. Moreover, the beneficial effects of teneligliptin on high glucose-induced cardiomyocytes were abolished by inhibiting AMPK, suggesting that the regulatory effect of teneligliptin on DCM was controlled by AMPK. In the future, the exact mechanism will be identified by treating diabetic mice with teneligliptin plus compound C. This limitation of the present study should be mentioned. The current study did not determine how teneligliptin interferes with AMPK/NLRP3 signaling in cardiomyocytes. It has been reported that NLRP3 plays an important role in cardiomyocyte pyroptosis during DCM. Future studies will further explore the effect of teneligliptin on cardiomyocyte pyroptosis during DCM. LCZ696 is a dual inhibitor of the AT1 receptor and of neprilysin signaling, and it remains unclear whether the effect of LCZ696 is dependent on these two pathways. The role of neprilysin in endothelial cells is not well known.

**CONCLUSION**

Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome, which suggests that in future clinical work, teneligliptin may treat diseases involving the NLRP3 pathway.

**Limitations**

This study showed that teneligliptin improves cardiac function in DCM *in vivo* and *in vitro* and exerts its effect through NLRP3. One shortcoming of this study is that the direct effect of NLRP3 was not verified by knocking down or overexpressing NLRP3.
addition, the effect of teneligliptin on NLRP3-induced autophagy will be examined in future studies.

ARTICLE HIGHLIGHTS

Research background
Diabetic cardiomyopathy (DCM), which is a complication of diabetes, poses a great threat to public health. Recent studies have confirmed the role of NOD-like receptor protein 3 (NLRP3) activation in DCM development through the inflammatory response. Teneligliptin is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor used to treat diabetes. Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells.

Research motivation
This study examined the therapeutic effects of teneligliptin on DCM in diabetic mice. Streptozocin (STZ) was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin.

Research objectives

Research methods
This study examined the therapeutic effects of teneligliptin on DCM in diabetic mice. Streptozocin (STZ) was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin.

Research results
Marked increases in cardiomyocyte area and heart weight/tibia length; reductions in fractional shortening, ejection fraction, and heart rate; increases in creatine kinase-MB
(CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels; and upregulated NADPH oxidase 4 (NOX-4) were observed in diabetic mice, all of which were significantly reversed by teneligliptin. Moreover, NLRP3 inflammasome activation and increased release of interleukin-1β (IL-1β) in diabetic mice were inhibited by teneligliptin. Primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5, 5 μM) for 24 h. NLRP3 inflammasome activation and the increases in CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes were markedly inhibited by teneligliptin, and p-adenosine 5’-monophosphate (AMP)-activated protein kinase (p-AMPK) levels were increased. Furthermore, the beneficial effects of teneligliptin on high glucose-induced cardiomyocytes were abolished by the AMPK signaling inhibitor compound C.

Research conclusions
Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome.

Research perspectives
Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome, which suggests that in future clinical work, teneligliptin may treat diseases involving the NLRP3 pathway.
### PRIMARY SOURCES

<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Words</th>
<th>Similarity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>pubmed.ncbi.nlm.nih.gov</td>
<td>79</td>
<td>2%</td>
</tr>
<tr>
<td>2</td>
<td><a href="http://www.researchgate.net">www.researchgate.net</a></td>
<td>33</td>
<td>1%</td>
</tr>
<tr>
<td>3</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>31</td>
<td>1%</td>
</tr>
<tr>
<td>4</td>
<td>Shao, Bo-Zong, Zhe-Qi Xu, Bin-Ze Han, Ding-Feng Su, and Chong Liu. &quot;NLRP3 inflammasome and its inhibitors: a review&quot;, Frontiers in Pharmacology, 2015. Crossref</td>
<td>22</td>
<td>1%</td>
</tr>
<tr>
<td>5</td>
<td>oaji.net</td>
<td>15</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>6</td>
<td><a href="http://www.nature.com">www.nature.com</a></td>
<td>14</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>7</td>
<td><a href="http://www.hindawi.com">www.hindawi.com</a></td>
<td>13</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>8</td>
<td><a href="http://www.mdpi.com">www.mdpi.com</a></td>
<td>13</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>9</td>
<td>docksci.com</td>
<td>12</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>